(资料图)
赛升药业公告，子公司赛而生物与海晶生物签署《技术合作开发合同》，交易总额为1160万元，合作完成达格列净片、达格列净二甲双胍缓释片的全面药学研究、临床注册申报、临床研究、生产注册申报等。
(资料图)
赛升药业公告，子公司赛而生物与海晶生物签署《技术合作开发合同》，交易总额为1160万元，合作完成达格列净片、达格列净二甲双胍缓释片的全面药学研究、临床注册申报、临床研究、生产注册申报等。
2022-12-29
2022-12-29
2022-12-29
2022-12-29
2022-12-28
2022-12-28
2022-12-28
2022-12-28
2022-12-27
2022-12-27
2022-12-27
2022-12-27
2022-12-26
2022-12-26
2022-12-26
2022-12-25
2022-12-24
2022-12-24
2022-12-23
2022-12-23
2022-12-23
2022-12-22
2022-12-22
2022-12-22
2022-12-21
2022-12-21
2022-12-20
2022-12-20
2022-12-20
2022-12-19
2022-12-19
2022-12-19
2022-12-18
2022-12-18
2022-12-17
2022-12-16
2022-12-16
2022-12-16
2022-12-15
2022-12-15
2022-12-15
2022-12-14
2022-12-14
2022-12-14
2022-12-13
2022-12-13
2022-12-12
2022-12-12
2022-12-10
2022-12-09
2022-12-07
2022-12-06
2022-08-07
2022-07-08
2022-05-20
2022-05-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03